A preprint using health records found BPC-157 users rose from about 54 in early 2022 to 1,018 in early 2026, and most waited two months to tell a doctor.
Recap by typeshit. Full story at The Verge.
European regulators first raised NAION, a rare optic nerve condition sometimes called an eye stroke, as a possible risk more than 15 months ago.
Obesity doctor Spencer Nadolsky takes on six popular misconceptions about Ozempic in a quick social video. The caption doesn't say which myths are covered.
Users described more appetite, fatigue, extra energy and insomnia. An analysis of Reddit comments, not a clinical trial, so the findings come from self-reports.
Online sellers pitch peptides for weight loss, anti-aging and muscle gain, and Gavin Coote's full story looks at the risks of products nobody regulates.
Dissolving strips are showing up in the peptide market. The Bee asks the FDA and researchers whether they are safe and actually work.
An investor analysis ranks five Lilly milestones by return. The 2008 ImClone deal turned $1,000 into about $58,000, while buying at Zepbound's approval returned 91%.
Loading…